UNSPSC 51151905: Carisoprodol

This classification denotes a muscle relaxant with the molecular formula C12H24N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 21925K482H, chemically known as 1,3-propanediol, 2-methyl-2-propyl-, carbamate isopropylcarbamate (ester) but generally known as carisoprodol, which bears US NIH Compound Identifier 2576. European Medicines Agency schedules Carisoprodol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06631MIG.

UNSPSC 51151905 Carisoprodol, a Commodity code, designates a specific muscle-relaxant pharmaceutical product, but the recent state and local opportunities tagged under it show minimal alignment with the code's nominal scope. The single concrete procurement opportunity—Seminole County, Florida's IFB60459723LAS for Naloxone and drug deactivation systems—targets opioid-overdose response supplies rather than carisoprodol, while a Texas Health and Human Services Commission RFI on direct-to-manufacturer prescriptions focuses on pharmacy benefit program architecture rather than procurement of a named pharmaceutical product. State and local agencies posting under this code appear to include county health departments and state human services commissions; however, the recent record is too sparse and misaligned to support a reliable characterization of issuing-body patterns or a credible scope-of-work summary grounded in what is actually being bought today.

The geographic footprint is limited to Florida and Texas based on the two posted opportunities. Seminole County's IFB, posted June 30, 2026, with a response deadline of July 26, 2023 (a historical discrepancy in the source), seeks annual delivery of naloxone and deactivation systems on a two-year contract with one-year renewal option. The Texas HHS RFI, posted April 3, 2026, is a preliminary information-gathering mechanism with no award value or formal evaluation timeline specified. Neither opportunity represents active procurement demand for carisoprodol itself, suggesting the code may be underutilized, misapplied, or relevant to a narrower specialist pharmaceutical supply chain than recent posting activity reflects. Business development professionals should verify whether carisoprodol procurement in state and local jurisdictions occurs under a different code classification or follows a separate pharmaceutical contracting pathway.